Limits...
Anti-Oxidative Effect of Myrtenal in Prevention and Treatment of Colon Cancer Induced by 1, 2-Dimethyl Hydrazine (DMH) in Experimental Animals.

Lokeshkumar B, Sathishkumar V, Nandakumar N, Rengarajan T, Madankumar A, Balasubramanian MP - Biomol Ther (Seoul) (2015)

Bottom Line: Monoterpenes are a major part of plant essential oils found largely in fruits, vegetables and herbs.The Invivo results exhibit the elevated antioxidant and lipid peroxidation levels in DMH treated animals.It is thus concluded that myrtenal exhibits excellent free radical scavenging activity and anticancer activity through the suppression of colon carcinoma in Wistar albino rats.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology and Environmental Toxicology, Dr. A. L. MPGIBMS, University of Madras, Taramani Campus, Chennai- 600 113, Tamilnadu, India.

ABSTRACT
Colon cancer is considered as the precarious forms of cancer in many developed countries, with few to no symptoms; the tumor is often diagnosed in the later stages of cancer. Monoterpenes are a major part of plant essential oils found largely in fruits, vegetables and herbs. The cellular and molecular activities show therapeutic progression that may reduce the risk of developing cancer by modulating the factors responsible for colon carcinogenesis. Colon cancer was induced with DMH with a dose of (20 mg/Kg/body weight) for 15 weeks by subcutaneous injection once in a week. Myrtenal treatment was started with (230 mg/Kg/body weight) by intragastric administration, one week prior to DMH induction and continued till the experimental period of 30 weeks. The Invivo results exhibit the elevated antioxidant and lipid peroxidation levels in DMH treated animals. The Histopathological analysis of colon tissues well supported the biochemical alterations and inevitably proves the protective role of Myrtenal. Treatment with myrtenal to cancer bearing animals resulted in a remarkable increase in the inherent antioxidants and excellent modulation in the morphological and physiological nature of the colon tissue. It is thus concluded that myrtenal exhibits excellent free radical scavenging activity and anticancer activity through the suppression of colon carcinoma in Wistar albino rats.

No MeSH data available.


Related in: MedlinePlus

Effect of myrtenal on Phase I & Phase II enzyme levels in liver of control and experimental animals. The levels of xenobiotic metabolizing enzymes in the liver of control and experimental animals are presented in the bar diagram. Liver metabolizing enzyme levels were found normal in group I control animals. Group II DMH induced animals express increased levels of phase I enzymes and decreased phase II enzymes. Myrtenal treated group III animals exhibit reversion of altered levels of phase I and phase II biotrans-formation enzymes to near normal compared to group II DMH induced animals. No significant changes were observed in group IV myrtenal alone treated animals. Results are expressed as mean ± S.D for six animals. aGroup II, III & IV compared with Group I. bGroup III compared with Group II.*p<0.05, NSNot Significant. Units: Cytochrome P450-n moles/mg microsomal protein/min; Cytoch rome b5-n moles/mg microsomal protein/min; GST- n moles/mg microsomal protein/min; UDP-GT- n moles/mg microsomal protein/min.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4556208&req=5

f3-bt-23-471: Effect of myrtenal on Phase I & Phase II enzyme levels in liver of control and experimental animals. The levels of xenobiotic metabolizing enzymes in the liver of control and experimental animals are presented in the bar diagram. Liver metabolizing enzyme levels were found normal in group I control animals. Group II DMH induced animals express increased levels of phase I enzymes and decreased phase II enzymes. Myrtenal treated group III animals exhibit reversion of altered levels of phase I and phase II biotrans-formation enzymes to near normal compared to group II DMH induced animals. No significant changes were observed in group IV myrtenal alone treated animals. Results are expressed as mean ± S.D for six animals. aGroup II, III & IV compared with Group I. bGroup III compared with Group II.*p<0.05, NSNot Significant. Units: Cytochrome P450-n moles/mg microsomal protein/min; Cytoch rome b5-n moles/mg microsomal protein/min; GST- n moles/mg microsomal protein/min; UDP-GT- n moles/mg microsomal protein/min.

Mentions: In group II colon cancer bearing animals Phase I enzyme levels were elevated compared to group I control. The activities of cytochrome P450 and cytochrome b5 were significantly decreased in myrtenal treated group III animals compared to group II cancer bearing animals in (Fig. 3). No significant changes were observed between group IV myrtenal alone treated animals and group I control animals. Phase II biotransformation enzymes projected decreased levels in group II cancer bearing animals compared to group I control animals. Group III myrtenal treated animals showed elevated levels of GST and UDP-GT compared to group II animals (Fig. 3). Group IV myrtenal alone treated animals and group I control animals showed no significant difference. Histopathological analysis of colons from rats treated with DMH in group II (Fig. 4B) showed differentiated signs of adenoma, with thickened epithelium and enlarged nuclei, DMH-induced colon tumor nearly restored to normal histoarchitecture, with a slight loss of nuclear polarity being evident following myrtenal treatment (Fig. 4C). Normal architecture with clear morphology was observed in (Fig. 4A) control animals and in (Fig. 4D) Myrtenal alone treated animals.


Anti-Oxidative Effect of Myrtenal in Prevention and Treatment of Colon Cancer Induced by 1, 2-Dimethyl Hydrazine (DMH) in Experimental Animals.

Lokeshkumar B, Sathishkumar V, Nandakumar N, Rengarajan T, Madankumar A, Balasubramanian MP - Biomol Ther (Seoul) (2015)

Effect of myrtenal on Phase I & Phase II enzyme levels in liver of control and experimental animals. The levels of xenobiotic metabolizing enzymes in the liver of control and experimental animals are presented in the bar diagram. Liver metabolizing enzyme levels were found normal in group I control animals. Group II DMH induced animals express increased levels of phase I enzymes and decreased phase II enzymes. Myrtenal treated group III animals exhibit reversion of altered levels of phase I and phase II biotrans-formation enzymes to near normal compared to group II DMH induced animals. No significant changes were observed in group IV myrtenal alone treated animals. Results are expressed as mean ± S.D for six animals. aGroup II, III & IV compared with Group I. bGroup III compared with Group II.*p<0.05, NSNot Significant. Units: Cytochrome P450-n moles/mg microsomal protein/min; Cytoch rome b5-n moles/mg microsomal protein/min; GST- n moles/mg microsomal protein/min; UDP-GT- n moles/mg microsomal protein/min.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4556208&req=5

f3-bt-23-471: Effect of myrtenal on Phase I & Phase II enzyme levels in liver of control and experimental animals. The levels of xenobiotic metabolizing enzymes in the liver of control and experimental animals are presented in the bar diagram. Liver metabolizing enzyme levels were found normal in group I control animals. Group II DMH induced animals express increased levels of phase I enzymes and decreased phase II enzymes. Myrtenal treated group III animals exhibit reversion of altered levels of phase I and phase II biotrans-formation enzymes to near normal compared to group II DMH induced animals. No significant changes were observed in group IV myrtenal alone treated animals. Results are expressed as mean ± S.D for six animals. aGroup II, III & IV compared with Group I. bGroup III compared with Group II.*p<0.05, NSNot Significant. Units: Cytochrome P450-n moles/mg microsomal protein/min; Cytoch rome b5-n moles/mg microsomal protein/min; GST- n moles/mg microsomal protein/min; UDP-GT- n moles/mg microsomal protein/min.
Mentions: In group II colon cancer bearing animals Phase I enzyme levels were elevated compared to group I control. The activities of cytochrome P450 and cytochrome b5 were significantly decreased in myrtenal treated group III animals compared to group II cancer bearing animals in (Fig. 3). No significant changes were observed between group IV myrtenal alone treated animals and group I control animals. Phase II biotransformation enzymes projected decreased levels in group II cancer bearing animals compared to group I control animals. Group III myrtenal treated animals showed elevated levels of GST and UDP-GT compared to group II animals (Fig. 3). Group IV myrtenal alone treated animals and group I control animals showed no significant difference. Histopathological analysis of colons from rats treated with DMH in group II (Fig. 4B) showed differentiated signs of adenoma, with thickened epithelium and enlarged nuclei, DMH-induced colon tumor nearly restored to normal histoarchitecture, with a slight loss of nuclear polarity being evident following myrtenal treatment (Fig. 4C). Normal architecture with clear morphology was observed in (Fig. 4A) control animals and in (Fig. 4D) Myrtenal alone treated animals.

Bottom Line: Monoterpenes are a major part of plant essential oils found largely in fruits, vegetables and herbs.The Invivo results exhibit the elevated antioxidant and lipid peroxidation levels in DMH treated animals.It is thus concluded that myrtenal exhibits excellent free radical scavenging activity and anticancer activity through the suppression of colon carcinoma in Wistar albino rats.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology and Environmental Toxicology, Dr. A. L. MPGIBMS, University of Madras, Taramani Campus, Chennai- 600 113, Tamilnadu, India.

ABSTRACT
Colon cancer is considered as the precarious forms of cancer in many developed countries, with few to no symptoms; the tumor is often diagnosed in the later stages of cancer. Monoterpenes are a major part of plant essential oils found largely in fruits, vegetables and herbs. The cellular and molecular activities show therapeutic progression that may reduce the risk of developing cancer by modulating the factors responsible for colon carcinogenesis. Colon cancer was induced with DMH with a dose of (20 mg/Kg/body weight) for 15 weeks by subcutaneous injection once in a week. Myrtenal treatment was started with (230 mg/Kg/body weight) by intragastric administration, one week prior to DMH induction and continued till the experimental period of 30 weeks. The Invivo results exhibit the elevated antioxidant and lipid peroxidation levels in DMH treated animals. The Histopathological analysis of colon tissues well supported the biochemical alterations and inevitably proves the protective role of Myrtenal. Treatment with myrtenal to cancer bearing animals resulted in a remarkable increase in the inherent antioxidants and excellent modulation in the morphological and physiological nature of the colon tissue. It is thus concluded that myrtenal exhibits excellent free radical scavenging activity and anticancer activity through the suppression of colon carcinoma in Wistar albino rats.

No MeSH data available.


Related in: MedlinePlus